Show simple item record

dc.contributor.authorMorey, Adrienne L
dc.contributor.authorBrown, Belinda
dc.contributor.authorFarshid, Gelareh
dc.contributor.authorFox, Stephen B
dc.contributor.authorFrancis, Glenn D
dc.contributor.authorMcCue, Glenda
dc.contributor.authorvon Neumann-Cosel, Vita
dc.contributor.authorBilous, Michael
dc.date.accessioned2019-03-31T23:48:13Z
dc.date.available2019-03-31T23:48:13Z
dc.date.issued2016
dc.identifier.issn0031-3025
dc.identifier.doi10.1016/j.pathol.2016.05.007
dc.identifier.urihttp://hdl.handle.net/10072/100720
dc.description.abstractAppropriate and accurate determination of HER2 status in women with breast cancer is critical for stratifying anti-HER2 therapies, and for access to subsidised treatment in the Australian setting. We conducted a regulated, nationwide program providing HER2 in situ hybridisation (ISH) testing for patients with newly diagnosed breast cancer. Cases with equivocal or non-diagnostic ISH test results at the local laboratory were sent to a high volume central testing laboratory for analysis using fluorescence ISH (FISH). We tested 78,408 early breast cancers and 3469 metastatic cancers using ISH. Of these, 12,405 early breast cancers (15.8%) and 798 metastatic cancers (23.0%) were HER2 positive. During the testing period, the proportion of core biopsy samples increased, the number of repeat tests remained stable and testing turnaround time declined. Discordant 3+ IHC, ISH negative results dropped from 20% to 13% in early breast cancers and from 35% to 8% among metastatic breast cancers. Following central laboratory FISH testing only 87 samples remained non-diagnostic (1.9% of FISH-tested samples, 0.1% of the whole cohort), most being decalcified specimens. This is a successful story of a cohesive service determining HER2 status in women with breast cancer in a ‘real-world’ setting.
dc.description.peerreviewedYes
dc.languageEnglish
dc.language.isoeng
dc.publisherAmerican Society for Clinical Pathology
dc.relation.ispartofpagefrom535
dc.relation.ispartofpageto542
dc.relation.ispartofissue6
dc.relation.ispartofjournalAnatomical Pathology
dc.relation.ispartofvolume48
dc.subject.fieldofresearchClinical sciences
dc.subject.fieldofresearchClinical sciences not elsewhere classified
dc.subject.fieldofresearchcode3202
dc.subject.fieldofresearchcode320299
dc.titleDetermining HER2 (ERBB2) amplification status in women with breast cancer: final results from the Australian in situ hybridisation program
dc.typeJournal article
dc.type.descriptionC1 - Articles
dc.type.codeC - Journal Articles
gro.hasfulltextNo Full Text
gro.griffith.authorFrancis, Glenn D.


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record